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Abstract: Gluten-free diet (GFD) is the only treatment for celiac disease (CD). There is a general
consensus that strict GFD adherence in CD patients leads to full clinical and histological remission
accompanied by improvement in quality of life and reduced long-term complications. Despite the
importance of monitoring the GFD, there are no clear guidelines for assessing the outcome or for
exploring its adherence. Available methods are insufficiently accurate to identify occasional gluten
exposure that may cause intestinal mucosal damage. Serological tests are highly sensitive and
specific for diagnosis, but do not predict recovery and are not useful for follow-up. The use of serial
endoscopies, it is invasive and impractical for frequent monitoring, and dietary interview can be
subjective. Therefore, the detection of gluten immunogenic peptides (GIP) in feces and urine have
been proposed as new non-invasive biomarkers to detect gluten intake and verify GFD compliance in
CD patients. These simple immunoassays in human samples could overcome some key unresolved
scientific and clinical problems in CD management. It is a significant advance that opens up new
possibilities for the clinicians to evaluate the CD treatment, GFD compliance, and improvement in
the quality of life of CD patients.
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1. Introduction
Gluten is a complex mixture of water insoluble proteins from wheat, barley, rye, and oats that
are damaging to celiac patients. The term gluten includes prolamins (gliadins in wheat) and glutelins
(glutenins in wheat). The prolamins, a complex group of alcohol-soluble proteins, constitute the major
seed proteins in cereals and comprise about 50% of the proteins in mature cereal grain. Other gluten
proteins showing that analogous immunogenic properties are present also in barley (hordeins), rye
(secalins), oats (avenins), and other-closely related grains [1–3]. These proteins are rich in proline
and glutamine residues, making them resistant to gastrointestinal digestion and encouraging the
deamination by tissue transglutaminase (tTG).
Celiac disease (CD) is an immune-mediated systemic disorder elicited by ingestion of gluten
in genetically-susceptible individuals. It affects around 1% of the population and it is based on a
variable combination of intestinal and extraintestinal signs and symptoms, celiac specific antibodies,
HLA-DQ2/DQ8 haplotypes, and enteropathy.
To date, the mainstay of CD is a lifelong strict gluten-free diet (GFD). There is a general consensus
that strict GFD adherence in CD patient results in complete histological and clinical remission and
an improvement in the quality of life and reduced long-term complications [4–6]. Thereby, the strict
adherence to GFD leads to significant improvement in bone density [7–10] and the normalization of
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vitamins (e.g., vitamin B12 among others) and minerals, although sometimes supplements may be
necessary to achieve optimum levels [11].
The gluten content in food is regulated by the Codex Alimentarius [12]. This regulation (CODEX
STAN 118—1979, revised in 2008) states that gluten-free foods are those in which the total levels of
gluten are ≤20 ppm [3]. Gluten-free cereals, such as rice, buckwheat, corn, and millet, can replace
gluten-containing cereals. Some legumes, such as amaranth, quinoa, and soybean, are especially
convenient due to their high protein content and quality. Moreover, non-processed food as fish,
meat, poultry, egg, vegetables, and fruit are recommended to promote GFD adherence and secure the
nutritional value of the diet [13].
Although conceptually simple, dietary changes are substantial and have a profound effect on
a patient's life. Indeed, there are barriers related with GFD, such as availability, cost, and safety of
gluten-free foods, or gluten cross-contamination [14,15]. Estimated compliance rates vary considerably
(17%–80%), depending on factors such as the patient’s age or the age at diagnosis of CD, among
others [16–19]. The poor dietary adherence has shown to be negative to promote other autoimmune
disease [20,21], fertility problems [22–24], and increased risk of bone fracture [25] or lymphoma [26,27].
Furthermore, after adoption of the GFD, 4%–30% of CD patients reported persisting symptoms and
are considered to be affected by nonresponsive CD (NRCD) [6]. However, only 10% of these NRCD
patients have refractory CD (RCD), being inadvertent or deliberate gluten exposure the most frequent
cause of NRCD [28].
Additionally, in the last decade CD research is changing rapidly as gluten-related disorders
have gradually emerged as an epidemiologically-relevant phenomenon with a global prevalence.
Such disorders include, besides CD, wheat allergy, which affects 0.2%–0.5% of the population [29], and
non-celiac gluten sensitivity (NCGS), a pathology in which gluten ingestion results in symptomatic
and morphological manifestations in the absence of CD and wheat allergy [30], with highly variable
incidence from 0.6% to 6% [31]. It has become more complex both the differential diagnosis and
monitoring of patients since the requirements of adherence to GFD vary in each of the disorders.
Moreover, this also makes more noticeable the dilemma of how to measure dietary transgressions.
Although the importance of monitoring the GFD, there are no clear guidelines for assessing the outcome
or for exploring its adherence. In addition, there is no consensus on the frequency of monitoring or the
suitable measurements for evaluating compliance and outcome [32]. A variety of surrogate markers are
available to assess the GFD compliance including clinical assessment of symptoms, patient self-report
about the level of adherence, dietary history, evaluation carried out by a professional nutritionist,
small-bowel biopsy, or serologic screening tests. Nevertheless, the lack of standardized and accurate
indicators of GFD adherence is a significant problem both in the clinic and in research.
In order to evaluate the recent literature relating to CD and the monitoring of GFD, a search of
scientific literature was conducted for recent publications on GFD compliance and CD. Based on these
updates, the aim of this paper is to show and discuss the current concepts on the available tools to
follow-up patients on GFD.
The search was conducted in PubMed MEDLINE and SCOPUS databases. The following search
terms were used: “celiac disease and gluten-free diet”, “follow-up celiac disease”, “monitoring
gluten-free diet”, and “management celiac disease”. The keywords “symptoms and celiac disease”,
“biopsy and celiac disease”, “serological test and celiac disease”, “questionnaire and celiac disease”,
“dietary interview and celiac disease”, “feces and celiac disease”, and “urine and celiac disease” were
also used.
2. Monitoring of Gluten-Free Diet Compliance
2.1. Symptom Assessment
Follow-up of initial symptoms or the manifestations of newly-developed ones serve to check
the improvement and evolution of CD. Intestinal bowel symptoms have been reported as common
Nutrients 2017, 9, 46 3 of 14
in CD patients not adherent to GFD (odds ratios 2.69; 95% confidence intervals 0.75–9.56) according
to a meta-analysis of seven studies, including more than 3000 subjects [33]. Although seemingly
intuitive, clinical response could not be a single method for monitoring adherence to the GFD as a
large number of celiac patients are asymptomatic or minimally symptomatic at presentation and in
these cases it would not be feasible to use clinical response as an indicator of mucosal healing and GFD
compliance [34]. A controlled study examining the effects of gluten challenge found that symptoms
were absent in 22% of celiac patients, despite the presence of significant villous atrophy in the small
bowel biopsy [35].
2.2. Validated Surveys and Dietary Interviews
The dietitian or dedicated physician is responsible for dietetic review. In addition to a number of
questionnaires evaluating food frequency and self-reported GFD adherence, there is a visual analogue
score scale which consists of an unmarked line with the anchor sentences ‘I never adhere to my diet’
and ‘I always adhere to my diet’ at each end [36–41]. Nonetheless, no quality control or standard
is available for dietetic review due to local diets and habits targeting a specific structured interview
related to the quality of the diet. To date, there is a lack of studies on GFD review outcomes in
different countries, and there is no evidence that a proper review can replace other tools (e.g., biopsy)
to predict mucosal damage. Moreover, individuals tend to inaccurately report their adherence level,
whether intentionally or not, so that dietetic review could be subjective and not identify involuntary
infringements [42,43].
2.3. Biopsies
Biopsies are a key component for diagnosis, and sometimes it is also necessary for monitoring.
During upper intestinal endoscopy at least one biopsy samples should be taken from the bulb and, at
least four biopsies, from the second or third portion of the duodenum. Typical features of CD include
an increase of intraepithelial lymphocytes (IELs), elongation of the crypts, and partial to total villous
atrophy. Therefore, a complete description of the orientation, number of IELs, the presence or not of
normal villi or degree of atrophy and crypt elongation, and grading according to the Marsh-Oberhuber
classification must appear in the pathology report [44]. The original Marsh classification [45] based on
normal mucosa (Marsh 0) to the appearance of lymphocytic infiltration (Marsh 1), crypt hyperplasia
(Marsh 2), and different levels of villous atrophy (Marsh 3a–c) results may be subjective. In the
last years the modifications made by Oberhuber [46], Corazza and Villanacci [47], Ensari et al. [48],
Villanacci [49], or by Ensari [50] have been proposed as more objective and practical. Both classifications
made by Corazza and Villanacci [47] and by Ensari [48] are practical and have proven to be useful
with good specificity and sensitivity, discriminating latent CD from patients with normal mucosa and
identifying those at an early stage. Moreover, Villanacci [51] points out the advantage of including
the term of “microscopic enteritis” as a separate histopathology diagnosis. Peña [52] provided a very
useful tabbed comparison between different classifications, allowing for compilation and analysis of
data for public health.
Classifications based on objective quantitative morphological parameters, such as measurements
of height-to-crypt-depth ratio and inflammatory variables, such as the density of IELs with a proper
protocol, have been welcome. Taavela et al. [53] evaluated these quantitative morphological and
inflammatory variables in the assessment of different degrees of damage to provide cut-off values
to be employed in routine clinical practice in CD. The subtyping of the IELs by histological and
immunological research and the utilization of flow cytometry and/or immunohistochemistry to the
study of IELs have been pointed out to be of paramount importance in the diagnosis and follow-up
of CD [54–56]. The ratio of the upper normal limit of IELs in the proximal small intestine used as a
criterion of the Marsh-Oberhuber classification for gluten sensitivity was established in 40 IELs per
100 epithelial cells (EC) [57]. However, recent studies have observed the upper normal limit in the
proximal small intestine to be as low as 20 IEL/100 EC at the tips of five villi on hematoxylin-eosin
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stained sections and 25 IEL/100 EC with immunohistochemistry by using more thinly cut sections of
3 µm and 4 µm and CD3 immunohistochemistry [58].
Despite the use of endoscopies to collect biopsies and assess mucosal healing being the gold
standard, it is an invasive, expensive, and impractical procedure for frequent monitoring of disease
activity or severity [59]. There are a proportion of cases difficult to monitor and evaluate with biopsy
because they have mild histological changes or there is a lack of concordance between serology and
histology. Therefore, the idea of re-assessing the emphasis on the biopsy as a gold standard in the
follow up of CD, in light of available less invasive tests, is a welcoming one. It has been reported that
complete recovery of duodenal mucosa extends over one year, with IELs frequent even 2–5 years after
celiac diagnosis [60]. Some experts do not routinely perform a follow-up biopsy in asymptomatic
patients with negative serology and good adherence [61]. However, inflammation of the intestinal
mucosa can occur long before the development of clinical signs or a rise in antibody titers following a
gluten challenge. On the other hand, in NRCD patients with absence of clinical response to a strict
GFD should prompt repeat biopsy and additional investigations [62]. Therefore, there is no consensus
on the role of follow-up biopsies [18,44].
2.4. Serological Tests
Anti-gliadin antibodies (AGA) were the first to be used as screening tool for the disease [63].
Since that time, serologic testing advanced from an adjunctive aid in diagnosis to an integral component
of diagnosis, management, and clinical research. Highly sensitive and specific tests, including tTG,
endomysial antibodies (EMA), and deamidated gliadin peptide (DGP) antibodies, have been identified
in optimizing diagnostics and screening studies [44]. Indeed, for all individuals in whom CD is being
considered, serological blood testing should be the initial step in evaluation [62,64]. Despite these
advances and the overall laudable test performance of EMA, tTG, and DGP for CD diagnosis, current
testing still is subject to a number of important limitations that are important for both clinicians and
researchers to recognize. One of the most practical issues currently faced by clinicians is the diversity
of available testing platforms, many of which have different cutoff levels, dynamic ranges, and overall
test performance. This issue, which has gone largely unaddressed, can be a major impediment to
both patient care and research when values are not comparable between providers or between studies.
Furthermore, monitoring disease activity in treated CD patients remains a challenge [64]. Although
the CD antibody tests show a high accuracy for selecting patients needing a diagnostic biopsy, these
tests do not seem to be reliable after diagnosis as the autoantibody titers do not correlate well with
histological findings or symptoms in CD patients on a GFD [34,65–70]. This may be due to their long
half-life and the fact that these titers reflect the immune response rather than direct intestinal damage.
IgA- and IgG-class tests can often take 6–24 months to decrease after the antigen source has been
eliminated from the diet. In addition, it is important to note that serological tests are not adequate
enough to show positive results in patients submitted to small or infrequent exposures to gluten [61].
2.5. Other Markers
Other studies suggested as suitable diet monitoring markers the permeability test, fecal
calprotectine, REG Iα or, recently, plasma total alkylresorcinols [71–74]. However, several studies
have reported these tests not being only specific to CD but also of limited efficacy in the diagnosis
of uncomplicated CD [75–77]. Two other markers are intestinal-fatty acid binding protein (I-FABP),
a marker reflecting enterocyte damage, and citrulline, a marker for functional enterocyte mass [64],
but they are not specific for CD, so they do not discriminate between a celiac relapse or other
gastrointestinal disorders in the patient.
Autoantibodies against pancreatic secretory-granule membrane glycoprotein 2 (GP2), especially
of IgA isotype, have been demonstrated in patients with Crohn’s disease and, recently, also with CD.
In CD patients with anti-GP2 antibody positivity, this marker could be used as indicator for intestinal
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inflammation and for follow-up. However, CD should be differentiated from Crohn’s disease by
parallel testing of CD-specific EMA or anti-tTG [78,79].
Recently, Ryan et al. [80] reviewed the metabolomics associated to the diagnosis and prognosis in
CD as a significant potential tool. The identification of three main components (malabsorption, energy
metabolism, and alterations of gut microbiota) in matrices, such as sera, urine, and feces, has been of
particular interest in the metabolome of CD. Different compounds related to malabsorption (decreased
levels of amino acids, lipids, pyruvate, and choline in the sera of celiac patients), other components
were related to energy metabolism (higher levels of glucose and 3-hydroxybutyric acid in sera) and,
thirdly, those related to alterations of gut microbiota and/or intestinal permeability as higher levels of
indoxyl sulfate, meta-[hydroxyphenyl] propionic acid, and phenylacetylglycine in urines [81,82].
2.6. Detection of Gluten Immunogenic Peptides (GIP)
The above tests to monitoring GFD compliance only evaluate the consequences of GFD
transgressions. Moreover, they are unable to detect occasional gluten exposure that may impede
total gut mucosa recovery in the celiac patient [34,65–67,83–88]. In this respect, it is noted that a diet
with zero gluten intake is impossible due to its ubiquity; thus, a minimal level of gluten contamination
is present in the daily diet. In fact, total daily gluten consumption that could be critical for most
CD patients is of <50 mg gluten [89], and some patients need as little as 10 mg of daily gluten to
promote development of intestinal mucosal abnormalities [90]. Therefore, there is a need for accurate,
non-invasive tools for managing patients to show gluten intake and avoid the harmful aftermaths.
CD is triggered by the certain gluten immunogenic peptides (GIP) are resistant to gastrointestinal
digestion and can interact with the immune system of patients with CD to trigger an autoimmune
response against tTG and other antigens. Shan et al. [91] showed by in vitro and in vivo studies in
rats and humans that a 33-mer peptide from α2-gliadin is stable toward breakdown by all gastric,
pancreatic, and intestinal brush border membrane endoproteases. This peptide was identified as
the primary initiator of the inflammatory response to gluten in patients with CD [91]. Toward the
assessment of toxicity and GIP in foods for celiac patients, G12 and A1 monoclonal antibodies (moAbs)
were obtained against 33-mer peptides. The reactivity of these antibodies was correlated with the
potential immunotoxicity of the proteins analyzed and they proved to be useful in studies about
the enzymatic detoxification of gluten [92,93]. These antibodies displayed a great sensitivity to
toxic peptides (besides the 33-mer peptide) from wheat, rye, barley, and varieties of oats [92,93].
A sandwich enzyme-linked immunosorbent assay (ELISA) based on G12 and A1 moAbs gave very
promising results for gluten analysis across a range of samples. This method had a limit of detection
of 0.6 ppm gluten, 1/3 of the concentration obtained by other methods described to date. Similarly,
a rapid test for the detection of gluten in solid food, drinks, and on surfaces using G12 moAb
lateral flow devices (LFD) or dipsticks [94,95], as well as a competitive ELISA method were also
developed for the detection of toxic gluten peptides in hydrolyzed foods [94,96]. More interesting, G12
immunodepletion experiments with hydrolyzed gliadin from beers showed that this moAb recognize
those with the highest immunoactivity for celiac patients, this is a significant advance in the detection
of the inmunoactive gluten content in the gluteome [97]. Based on these methodologies, new tools
have been proposed for monitoring the GFD by determining GIP in human samples.
2.6.1. Feces
Immunoassays with G12 moAb showed that >30% of the inmunoreactive gliadin peptides
persisted intact after hydrolysis during in vitro simulated gastrointestinal digestion [98]. Based on
these findings, Comino et al. [98] described a novel method to monitor the GFD by detection of GIP
in feces by using the G12 antibody [99]. This study supports the resistance of the 33-mer to in vitro
peptic-tryptic-chymotryptic hydrolysis; and, most significantly, it was shown that toxic epitopes
of gluten are measurable by moAbs in the feces of normal subjects and CD patients receiving a
gluten-containing diet. The resistance of gluten peptides to gastrointestinal digestion, in particular
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peptides related to the immunotoxic 33-mer peptide, ensures that an important part of the ingested
gluten is eliminated in feces. Consequently, the recovery of measurable levels of the immunotoxic
fraction in feces suggests that gluten has passed through the digestive tract and, therefore, that
gluten has been ingested. GIP were detected in the feces of healthy individuals and CD patients
receiving gluten-containing diets, and GIP disappeared when a GFD was introduced [100]. With diets
that contained variable quantities of gluten, GIP excretion was proportional to the amount ingested.
These tests could also detect differences when, being in GFD, subjects were challenged with known
amounts of oral gluten [98].
A recent study has shown the clinical usefulness of this new method of measuring fecal GIP as a
marker of adherence to GFD [43]. A multicenter clinical trial prospectively examined the compliance
to the GFD of both celiac children and adults. Furthermore, the response rate to GFD was evaluated
by dietary questionnaire, celiac serology, and clinical response. Correlations between fecal GIP and
traditional methods to monitoring the GFD were investigated. The majority (85.7%) of celiac children
between zero and three years of age had feces negative for GIP, with only 14.3% showing levels above
the limit of quantification. The proportion of celiac patients with feces positive for GIP increased to
27.8% in children between four and 12 years of age. Among those ≥13 years old, the proportion rose
up to 39.2% with positive GIP. When further stratified by gender, adherence to the GFD was found to
be closely related to the patient’s gender in certain age groups. More males ≥13-years old had positive
GIP feces compared with females in the same age group (60% vs. 31.5%, p = 0.034), indicating higher
numbers of dietary transgressions among males than in their female peers (Figure 1). Although no
overall significant differences between the percentage of GIP-positive feces in celiac patients and the
duration of the GFD were observed, the patients who had been on the GFD for a longer period of time
showed higher rates of noncompliance. No significant association was found between GIP levels in
celiac patients and history of CD in their first- or second-degree relatives.
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GIP/g feces, grey bar), and negative (<0.16 μg GIP/g feces, white bar). 
Comino et al. [43] also showed no association between fecal GIP and dietary questionnaires or 
anti‐tTG  antibodies. However,  association was  detected  between GIP  and  anti‐DGP  antibodies, 
although 46 of  the 53 GIP  feces‐positive patients were negative  for anti‐DGP. Detection of gluten 
peptides  in  feces reveals  limitations of  traditional methods  for monitoring GFD  in celiac patients. 
Fecal GIP analysis  is an accurate and noninvasive method  that  enables a direct and quantitative 
assessment  of  gluten  exposure  early  after  ingestion.  Therefore,  these methods  could  aid  in  the 
diagnosis and clinical management of NRCD and RCD [43]. 
Figure 1. Percentage distribution of celiac patients by GIP content in feces by age and sex. GIP, gluten
immunogenic peptides. GIP positive (>0.30 µg GIP/g feces, black bar), weak positive (0.16–0.30 µg
GIP/g feces, grey bar), and negative (<0.16 µg GIP/g feces, white bar).
Comino et al. [43] also showed no association between f cal IP and dietary questi nnaires
or nti-tTG antibodies. How ver, association was detect d between GIP and anti-DGP antibodies,
although 46 of the 53 GIP feces-positive patients were negative for anti-DGP. Detection of gluten
peptides in feces reveals limitations of traditional methods for monitoring GFD in celiac patients.
Fecal GIP analysis is an accurate and noninvasive method that enables a direct and quantitative
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assessment of gluten exposure early after ingestion. Therefore, these methods could aid in the
diagnosis and clinical management of NRCD and RCD [43].
2.6.2. Urine
A proportional fraction of the GIP absorbed in the gastrointestinal tract makes it to the circulation
and is excreted in urine [101,102]. The methodology proposed by Moreno et al. [103] based on urine
gluten testing may be useful in clinical practice as a monitoring tool to follow-up the compliance of
GFD. Clinical assays in urine based on LFD are used in many diseases. Coupling a reader to the LFD
in urine of CD patients could provide a quantitative measurement of dietary infringement, providing
significant advantages in the management of GFD. A positive correlation between the amount of
ingested gluten and GIP detected in human urine samples has been demonstrated [103]. It has been
determined in urine the low intake of gluten in processed bread, >25 mg corresponding to the lower
limit to exert damage to most celiac patients. GIP were detected in urine samples 6–48 h after gluten
intake. The methodology demonstrated the high level of noncompliance in patients with CD who
had supposedly consumed long-term GFD through the presence of GIP (48% and 45% in adults and
children, respectively). These results were consistent with reports showing that ~30%–50% continue
with mucosal atrophy in CD patients despite following a GFD [5,104–106]. More interestingly, a direct
correlation was demonstrated between the absence of GIP in urine and healing of the gut intestinal
epithelium (Figure 2). Furthermore, 100% of the adult patients with higher damage in the epithelia
(Marsh II/III), according to the histological analysis, had GIP in urine. In accordance with other
above-mentioned studies [34,67,85], this study confirmed the poor correlation of serological tests
with mucosal healing, as well as the shortcomings of the dietary history questionnaires to assess
GFD compliance.
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Figure 2. Presenc of GIP in urine of adult CD patients and correlation with the r small bowe histology.
Severity of mucosal lesion (Marsh I–III) and istological appearance determin by the Marsh scale.
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in urine (>QL). p = 0.0007 (Fisher’s exact test). Values are expressed as the percentage of patients. CD,
celiac disease; GIP, gluten immunogenic peptides; LDT, limit of technique detection; QL, quantification
limit. Modified according to Moreno et al. [103].
The development of point-of care devices for an accurate, simple, and efficient GFD monitoring
motived the creation of the highly-sensitive surface plasmon resonance biosensor for the detection of
GIP in urine [107]. The easy-to-handle samples, such as urine and user-friendly biosensors could be
suitable for the portable nd simple devices for the GFD compliance of celiac patients. Soler et al. [107]
demonstrated that the sensing methodology enables rapid and label-free quant fication of the GIP in
urine by using G12 moAb, reaching a limit of detection of 0.33 /mL. This study also clearly differed
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gluten consumers from non-consumers by measuring several urine samples from both healthy (normal
diet) and celiac subjects (GFD). Therefore, biosensors offer significant advantages over conventional
techniques enabling biochemical analysis with excellent reproducibility and high sensitivity in a matter
of minutes.
3. Conclusions and Future Directions
It is often difficult to evaluate compliance with GFD. Persistent gluten exposure is usually
unintentional. Exposure may occur no matter how careful a patient is, due to cross-contamination or
simple lack of knowledge regarding the diet. Serum markers for CD play an important role in CD
management (mostly tTG); however, the evidence suggests that it is not sensitive enough to detect
occasional significant dietary transgressions that impede mucosa healing. There is no agreement
on the role of follow-up biopsies and it is an invasive procedure, expensive and impractical for
frequent monitoring of this disease. Moreover, an issue to address is the lack of studies comparing
diagnostic efficacy of biomarkers with histology in patient follow-up. Notwithstanding, the need for
non-invasive approaches to monitor CD is certainly warranted. Some studies related to metabolomics
and other recent markers can measure the consequences of dietary transgressions, but they cannot
show direct gluten intake, and they are not specific for CD. The incorporation of simple immunological
assays based on GIP analysis in human samples could resolve some scientific and clinical problems
in CD management such as (i) detection of inadvertent lapses after appearance of acute symptoms;
(ii) in celiac patients, with or without symptoms, and patients with non-celiac gluten sensitivity;
(iii) non-compliance of the GFD before any anatomic damage; (iv) to prove gluten intake during CD
diagnosis; (v) examining the adherence to the GFD in the initial period after diagnosis when patients
are less familiar with this diet; and (vi) the accurate diagnosis and management of the diet in NRCD
and RCD. Therefore, these tests may prevent a potentially invasive and extensive medical analysis to
assess the cause of the ongoing symptoms of celiac patients.
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